Introduction
Human cytomegalovirus (HCMV) represents a significant cause of morbidity and mortality in immunocompromised hosts (Ho, 1982) . The envelope glycoproteins of viruses are often involved in the attachment to and penetration of the host cell and thus envelope glycoproteins of HCMV are likely to be important targets of the immune response to HCMV. It has been established that HCMV contains several families of disulphide-linked glycoprotein complexes as well as individual glycoproteins in its envelope (Gretch et al., 1988a; Kari et al., 1986) . One of the families of complexes, which we designated gC-I (Gretch et al., 1988a) , contains glycoproteins encoded by the gene designated as being the homologue of herpes simplex virus gB (Cranage et al., 1986) . Thus, the gC-I designation identifies the family of complexes and gB the glycoproteins within the complexes. The gC-I family consists of three complexes which have Mrs of 150000, 180000 and 250000, respectively (Farrar & Greenaway, 1986) . The 180000 Mr complex contained two glycoproteins with MrS of 52 000 (gp52) and 130 000 (gp130), respectively, associated by disulphide bonds. Both the 150000 and the 250000 Mr complexes contained gp52 and a 93000 to 95000 Mr glycoprotein (gp93) associated by disulphide bonds. The 250000 Mr complex appears to be a dimer of the 150000 Mr complex (Farrar & Greenaway, 1986; Taylor et al., 1988) . Pulse--chase studies using radioactive precursors and studies using inhibitors of glycosylation suggested that gp52, gp93 and gpl30 arise from a single gene product (Britt & Auger, 1986; Britt & Vugler, 1989; Gretch et al., 1988b; Taylor et al., 1988) . Analysis of these glycoproteins shows that gp52, which contains a transmembrane domain for anchoring it in the viral envelope (Spaete et al., 1988) , is encoded by the carboxyterminal region of the gB gene. Based on the studies described above, the N-terminal portion of the gene most likely codes for gp93-130, but this has not been established.
Since the exact relationships among the different glycoproteins of the gC-I complexes have not been fully defined we have further characterized them using murine monoclonal antibodies (MAbs). We were also interested in investigating the potential importance of antibody responses to the various gC-I glycoproteins. The data presented in this report show that gp52 and gp93-130 arise from a single gene product. In addition, both gp52 and gp93-130 contain epitopes which are recognized by neutralizing MAbs.
The MAbs were also used to analyse the tertiary and quaternary structure of the gC-I complexes. It has been demonstrated that some viral envelope proteins do not exist in the membrane as disulphide-linked complexes but form these bridges after they are extracted from the viral envelope (Pinter et al., 1978) . When extracted from the envelope of HCMV, gC-I consists of at least three complexes which differ in composition. As stated above, some complexes are heterodimers of gp52 plus gp93 and some appear to form multimers that are complexes containing two copies of gp52 and two copies of gp93. This suggested that two types of disulphide bridges were present, those between individual glycoproteins within complexes and those between complexes. We isolated the gC-I complexes under different conditions and determined that there are two types of disulphide bonds present in gC-I complexes. One type is very susceptible to reduction and appears to form inter-complex disulphide bonds. The second type is much more resistant to reduction and appears to form intra-complex disulphide bonds.
Methods
Preparation of Towne strain HCMV. Towne strain HCMV was grown on human skin fibroblasts as previously described (Kari et al., 1986) and virions were harvested from the culture medium. Cells were removed by low-speed centrifugation and the virions collected by ultracentrifugation. Virions were labelled by growth with [3H]GlcN (Amersham).
Monoclonal antibodies.
MAbs to gp52 and gp93-130 were generated and characterized as described previously (Kari et al., 1986; Lussenhop et al., 1988) . To make MAbs to gp93-130, gC-I was immunoaffinitypurified as described below, purified gC-I complexes were reduced and individual proteins separated by SDS-PAGE. Proteins were detected by Coomassie blue staining. Glycoprotein gp93-130 was electroeluted from the gel and used as antigen to immunize mice and for screening of hybridomas.
Neutralization assays. MAbs were purified by Protein G and tested for neutralizing activity against Towne strain HCMV in a plaque reduction assay as previously described (Lussenhop et al, 1988) . Approximately 1000 to 2000 p.f.u, were used in a 36 mm dish. Viral neutralization was evaluated by using the formula, percent plaque reduction = [(average maximum p.f.u. -test p.f.u.)/average maximum p.f.u.] x 100, and is reported as the protein concentration required for a 50~ reduction in plaque number.
Generation of vaccinia virus-gB recombinants and the C-terminal deletion mutant m165.
The construction of recombinant vaccinia virus was achieved by developed techniques (Mackett et al., 1987) . Briefly, an XmalII fragment (3125 bp) containing the gB gene obtained from Towne strain HCMV was cloned into the Sinai site of the pSCll vaccinia virus vector (from B. Moss, NIH, Bethesda, Md., U.S.A.). The procedure followed was originally described by Cranage et al. (1986) for HCMV strain AD169. The vector was then introduced into vaccinia virus through homologous recombination by transfection with the pSC11-gB recombinant and co-infection with wild-type vaccinia virus. The resulting thymidine kinase-negative recombinant virus was selected in HuTK-143 cells in the presence of 25 I~g/ml of bromodeoxyuridine (BUdR). Viruses were stained with 320 I~g/ml of 5-bromo-4-chloro-3-indolyl fl-D-galactopyranoside (X-Gal). Blue plaques were selected and purified three times on HuTK-143 cells in the presence of BUdR. The C-terminal deletion mutant ofgB, gBm165, was generated by infecting pSCl l-gB recombinant-carrying Escherichia coli DH1 cells with 467 : : Tn5 phage. The plasmids carrying the Tn5 transposon were selected by kanamycin resistance and screened as described (de Bruijn & Lupski, 1984; Weber et al., 1987) . The physical location of the Tn5 insertion was obtained by restriction enzyme analysis, which was shown to be able to map the insertion site to within 50 bp of the actual nucleotide (Smiley et at., 1982) . The precise site of insertion was determined by the dsDNA sequencing technique using a primer approximately 50 to 100 nucleotides from the insertion area. The gB mutant m165 used in this study had Tn5 inserted at nucleotide location 1539, which corresponded to amino acid 513.
Preparation of cells infected with vaccinia virus recombinants for
immunofluorescence studies. Subconfluent HuTK-143 ceils in chamber slides were infected with vaccinia virus recombinants including vaccinia-pSCll, vaccinia~B and vaccinia-gBm165 at an m.o.i, of 0.1. At 2 days post-infection the cells were fixed with cold methanolacetone (1:1), stained by incubation with either a gp52-specific MAb (41C2) or a gp93-130-specific MAb (3C2) and washed and incubated with fluorescein isothiocyanate-labelled goat anti-mouse IgG. Following a final wash, cells were examined with a Zeiss phase fluorescence microscope.
Purification of gC-I from Towne strain HCMV. The gC-I complexes were isolated by a modification of an immunoaffinity method using biotinylated MAbs and streptavidin agarose (Gretch et al., 1987) . Briefly, virions were extracted with a Tris HC1 buffer pH 7.5 containing 10mM-NaC1 and 1.0~ NP40 and the extract was centrifuged to remove insoluble material. A biotinylated MAb was added to 1.0~ NP40 extracts containing gC-I and incubated for 30 min before the addition of streptavidin agarose. This mixture was allowed to react for an additional 45 min with constant mixing. The agarose beads were pelleted by centrifugation and then washed with phosphatebuffered saline (PBS) containing 0.1~ NP40 and twice with PBS. Proteins were eluted from the bound antibody by heating at 100 °C in sample solubilization buffer (0-2 M-Tris-HC1 pH 6.8 containing 4~ SDS) for 3 rain to enable them to be electrophoresed.
SDS-PAGE andfluorography.
Radioactively labelled immunoprecipirated glycoproteins were separated by SDS PAGE in 10~ polyacrylamide gels using the method of Laemmli (1970) . Radioactivity in gels was detected by fluorography using EN3HANCE (New England Nuclear). Fluorographs were scanned with a Hoefer Scientific GS300 scanning densitometer.
Western blot analysis. A mini gel apparatus (Bio-Rad) was used for Western blotting. Glycoproteins were separated in 10~ polyacrylamide gels. After electroblotting onto nitrocellulose, the paper was blocked with 3~ gelatin in Tris-buffered saline (TBS; 20mM-Tris-HC1, 500 mM-NaCI pH 7-5). MAbs in ascitic fluid were diluted 1/500 in 1~ gelatin in TBS. Diluted MAbs were incubated with the paper overnight, after which the paper was washed with TBS containing 0-05~ Tween 20. Phosphatase-labelled goat anti-mouse IgG (Kirkegaard & Perry), diluted 1/1000 with 1 ~ gelatin in TBS, was added and allowed to react for 1 h, the paper was washed and the substrate 5-bromo-4-chloro-3-indolyl phosphate/tetrazolium in 0.1 M-Tris buffer (Kirkegaard & Perry) was added. After visualization of bands, the reaction was stopped by immersion in water.
Dithiothreitol (DTT) treatment of whole virus. Aliquots of purified
[3H]GlcN-labelled virions were suspended in PBS (pH 7.5) containing 50 mM-DTT and allowed to react at room temperature for 30, 60, 90 or 120 min with constant mixing. Excess iodoacetamide was added, the reaction was left for 30 rain and virions were collected by centrifugation. The pellet was washed to remove residual reagents. As a control, virions were also exposed to iodoacetamide without prior treatment with DTT. Virions were then extracted as described above and gC-I complexes immunoprecipitated. Immunoprecipitations were first performed with a gp52-specific MAb (41C2), followed by a gp93-specific MAb (3C2).
Galactose oxidase labelling. Purified extracellular virions were labelled with tritiated borohydride after treatment with galactose oxidase following the methods of Gahmberg & Hakomori (1973) . Briefly, whole virions in PBS (pH 7.5) were treated with 10 units of galactose oxidase (Sigma) for 1 h at room temperature. Virions were then treated with 3.3 mCi of tritiated borohydride (600 mCi/mmol; New England Nuclear) for 30 min. Excess borohydride was destroyed with 25% acetic acid (100 p.1) at 0 °C. Virions were then collected by centrifugation and washed with PBS.
R e s u l t s

Immunoprecipitation and Western blot analysis of gC-I complexes
For i m m u n o p r e c i p i t a t i o n s , virions were grown with
[3H]GlcN, purified, extracted with 1-0% N P 4 0 and insoluble material was then removed by centrifugation. These extracts were i m m u n o p r e c i p i t a t e d with M A b s recognizing gp52 (18F9) or gp93-130 (3C2 and 9F9) and an SP2 ascites was used as a negative control; the latter did not i m m u n o p r e c i p i t a t e any glycoproteins ( Fig. 1 a, b , lanes 1). All gp52-specific or gp93-130-specific M A b s i m m u n o p r e c i p i t a t e d complexes with Mrs ranging from 150000 to 250000 as detected by S D S -P A G E u n d e r nonreducing conditions (Fig. l a, lanes 2 to 4) . These complexes tended to form broad bands when e x a m i n e d by S D S -P A G E . After reduction, glycoproteins with Mrs of 52 000 (gp52), 93 000 to 130 000 (gp93-130) a n d 158 000 (gp158) were detected (Fig. lb, lanes 2 to 4) . Serial i m m u n o p r e c i p i t a t i o n s of unreduced complexes were done with these three MAbs. Regardless of whether a gp52-specific or a gp93-130-specific M A b was used for the initial i m m u n o p r e c i p i t a t i o n , little radioactivity was i m m u n o p r e c i p i t a t e d with a second M A b reactive with the other glycoprotein, showing that these M A b s recognized the same gC-I complexes ( Fig. 1 c, lanes 1 to  3) . These data also showed that these gC-I complexes all contained both gp52 and gp93-130.
To determine which individual gC-I glycoproteins were recognized by the MAbs, Western blot analysis was performed using immunoaffinity-purified gC-I as an antigen which had been reduced and its individual (a) (b) (c) . gC-I complexes were immunoah'inity-purified from a non-ionic detergent extract of Towne strain HCMV. Approximately 100 ktg of gC-I was reduced and gC-I glycoproteins were separated by SDS-PAGE in a 9~ polyacrylamide gel. Proteins were then electroblotted onto nitrocellulose paper, the paper was cut into strips and the strips were incubated with the negative control SP2 or MAbs. Lane 1 shows a portion of the gel which was cut off and stained with Coomassie blue. Lane 2, SP2 negative ascites control; lanes 3 and 4, gp93-speeific MAbs 3C2 and 9F9, respectively; lanes 5 to 7, gp52-specific MAbs 39Ell, 9B7 and 18F9, respectively. Numbers to the right and left indicate MrS x 10 -3. * Amount of MAb in p.g/ml needed to reduce the number of Towne HCMV plaques by 50~ with complement (+C') or without complement (-C'). MAbs were purified with a Protein G column. Each MAb was tested in a range of 1 to 100 p.g/ml of antibody with or without guinea-pig complement. Approximately 1000 p.f.u, of Towne HCMV were used in a 36 mm dish. proteins separated by SDS-PAGE. A portion of the gel was cut off and stained with Coomassie blue to detect proteins whereas the other portion of the gel was used for Western blot analysis. The proteins detected by Coomassie blue staining included gp52, gp93-130 and gp158. However, gp52 and gp93-130 were the most abundant glycoproteins detected (Fig. 2, lane 1) . Western blot analysis was performed with ascites fluid containing MAbs. An SP2 ascites used as a negative control did not react (Fig. 2, lane 2) . MAbs made against gp93-130 (3C2 and 9F9) reacted with the broad band designated gp93-130 and gp158, as well as material at the top of the strip (Fig. 2, lanes 3 and 4) . The material at the top of the strip may have been aggregates of gp93-130 because this material was not recognized by gp52 MAbs. In contrast, the MAbs recognizing gp52 (39E11, 9B7 and 18F9) also recognized gp158 (Fig. 2, lanes 5 to 7) . Therefore, gC-I contained two immunologically distinct glycoproteins, gp52 and gp93-130. However, gp158 is immunologically related to both gp52 and gp93-130. Based on its Mr and the fact that gp158 was recognized by both gp52 and gp93-130 MAbs, it appeared that gp158 was a precursor glycoprotein. Its presence may have been due to cellular membranes contaminating the viral preparation.
(g)
.
Reactivity of MAbs with gB recombinant proteins
Cells infected with vaccinia virus recombinants containing the entire gB open reading frame (ORF) (vacciniagB) and the C-terminal deletion of gB (vacciniagBm165), obtained by Tn5 transposition mutagenesis, was analysed by immunofluorescence using gp52 and gp93-130 MAbs. A C-terminal deletion was used to eliminate epitopes recognized by gp52 MAbs. The Cterminal portion of the gene encodes gp52, which starts at amino acid 461 and runs to the C terminus (Spaete et al., 1988) . MAbs recognizing gp52 or gp93-130 did not detect viral antigens in cells infected with vacciniapSC11 which was used as a negative control (Fig. 3a, b) . However, reactivity was detected with both gp52 and gp93-130 MAbs in cells infected with vaccinia-gB (Fig.  3c, d ) and with gp93-130 MAbs in cells infected with vaccinia-gBm165 (Fig. 3e, f) , which contained the first 513 amino acids of the N-terminal portion of gB according to restriction enzyme and sequence analysis. These data show that gp52 and gp93-130 are derived from the same gene and that the epitopes recognized by gp93-130 MAbs are located on the N-terminal portion of gB.
Neutralization analysis of murine MAbs
There have been several reports describing neutralizing MAbs which recognize gp52 (Banks et al., 1989; Britt, 1984; Britt et al., 1988; Lussenhop et al., 1988; Rassmussen et al., 1985) . However, there have been no reports describing MAbs recognizing gp93-130 that neutralize HCMV. Therefore, we analysed our gp52 and gp93-130 MAbs for their ability to neutralize Towne strain HCMV, in the presence and absence of complement, in an in vitro plaque reduction assay. As we previously reported (Lussenhop et al., 1988) , three MAbs recognizing continuous epitopes on gp52 (39Ell, 9B7 and 18F9) neutralized Towne strain HCMV, but only in the presence of complement. Data for 18F9 are also presented in Table 1 . Neutralization data for 39E 11, 9B7 and 18F9 have been previously reported (Lussenhop et al., 1988) . In contrast, MAbs (3C2 and 9F9) which recognized gp93-130 neutralized Towne strain HCMV in the absence of complement (Table 1) . Therefore, both gp52 and gp93-130 contain epitopes recognized by neutralizing MAbs but the mechanism of neutralization appears to be different.
gp93-130 is glycosylated differently from gp52
To determine whether gp52 and gp93-130 in the gC-I complexes were accessible on the surface of the virus and to characterize further the glycoproteins present in these complexes, extracellular virus was treated with galactose oxidase and oxidized residues were reduced with tritiated borohydride. This method was selected because it has been shown that gp93-130 contains O-linked oligosaccharides (Britt & Vugler, 1989; Kari & Gehrz, 1988) . After labelling, virions were extracted with 1.0% NP40 and gC-I complexes were immunoprecipitated from these extracts. No radioactivity was incorporated into the gC-I complexes when galactose oxidase was omitted from the reaction, demonstrating the specificity of the reaction (Fig. 4a, b, lanes 1) . When galactose oxidase and [3H]GlcN were used in non-reducing conditions, gC-I complexes with Mrs of 150000 to 250000 were labelled (Fig. 4a, lane 2; Fig. 4c, lane 1) , showing that gC-I complexes are present on the surface of the viral envelope. After reduction of galactose oxidaselabelled gC-I complexes, gp93-130 and gp 158 were found to contain label, whereas gp52 did not (Fig. 4b, lane 2) and, although gp52 was not labelled by this method, it was labelled, along with gp93-130 and gp 158, by growing virus in the presence of [3H]GlcN (Fig. 4c, lane 2) .
[3H]GlcN was probably incorporated into N-linked oligosaccharides on gp52, whereas this glycoprotein does not contain O-linked oligosaccharides and, therefore, cannot be labelled by the galactose oxidase method. Therefore, gp93-130 is a glycoprotein that has O-linked glycans and is glycosylated differently from gp52.
Analysis of disulphide bonds in gC-I complexes
Previous analysis has suggested that the envelope of HCMV contains dimers of gC-I complexes (Farrar & Greenaway, 1986) . These dimers were the species with the greatest Mr detected by SDS-PAGE, having an apparent Mr of 250000. We analysed the conditions under which these complexes could be obtained from virions to determine whether they cross-linked before or after isolation of the gC-I complexes. This was done by extracting gC-I complexes in the presence of iodoacetamide to prevent disulphide bond formation during isolation and by exposing virions to reducing agents prior to extraction of the gC-I complexes. To do this, virions were treated with DTT for 30, 60, 90 and 120 min, then by iodoacetamide, and collected by centrifugation. As a control, virions were treated with the same buffers and iodoacetamide but DTT was omitted, gp93-130 may have been released from the virions by treatment with DTT so these initial supernatants were analysed for the presence of free gp93-130; none was detected (data not shown). The DTT-treated virions were then extracted with 1.0% NP40, insoluble material was removed by centrifugation and extracts were immunoprecipitated with a gp52 MAb (41C2), followed by a gp93-130 MAb (3C2).
Immunoprecipitates obtained from the NP40 extracts were examined by SDS-PAGE and fluorography under non-reducing and reducing conditions. Fluorograms were exposed for 5 days and 2 to 3 weeks in order to detect all changes in the relative amounts of the virions gC-I glycoproteins. This was particularly important with regard to gp52 which was not as heavily glycosylated as gp93-130. Examination of the control virus sample by SDS-PAGE under non-reducing conditions (Fig. 5a , lane 1), showed that it contained complexes with Mrs of 150000 to 250000. These data suggest that the disulphide bonds in the 250 000 Mr complexes were not formed after extraction from the envelope of HCMV, but were originally present. However, when immunoprecipitates from DTT-treated virions were examined by SDS-PAGE, the 250 000 Mr complexes were almost completely lost whereas the amount of the 150000 to 180000 Mr 5) . At the end of each time period, excess iodoacetamide was added. Virions were collected by centrifugation and extraction with 1-0% NP40. These extracts were immunoprecipitated with a gp52 MAb, 41C2. Immunoprecipitated gC-I complexes were examined by SDS-PAGE under non-reducing and reducing conditions followed by fluorography. (a) gC-I complexes examined under non-reducing conditions. This fiuorogram was exposed for 3 weeks in order to detect the increase in free gp52 with increasing exposure of the virus to DTT. (b) A duplicate ftuorogram which was only exposed for 5 days was scanned with a densitometer to detect changes in the relative amounts of the 250000 and the 150000 to 180000 Mr complexes. The fluorogram lane scanned is indicated below each scan. The peak indicated by an arrow to the right in each scan indicates the point at which the scan was initiated on the fluorogram. Peak 1 is the 250000 M r complex, peak 2 the 150000 to 180000 Mr complex, peak 3 gp93 and peak 4 gp52. (c) This figure is the same as (a) except reducing conditions were used and the fluorogram was exposed for only 2 weeks.
complexes increased in relative amount (Fig. 5a , b, lane 2). This occurred within 30 min of exposure to DTT. Some of the 150000 to 180000 Mr complexes were still present after 120 min of exposure to DTT (Fig. 5a ). This suggested that reduction of the disulphide bonds forming these complexes was much slower than reduction of disulphide bonds forming the 250000 Mr complexes. However, a scan of a fluorogram exposed for 5 days showed that the amount of the 150000 to 180000 Mr complexes decreased between 30 and 120 min of DTT exposure (Fig. 5 b, lanes 2 to 5) . As the relative amount of these complexes decreased, the relative amount of gp93-130 and gp52, which dissociated from the complexes, increased, as shown by SDS-PAGE performed under non-reducing conditions (Fig. 5a , b, lanes 2 to 5). The complete change in the relative amount of free gp52 was only clearly detected after a 3 week exposure of the fluorogram and thus some of the early increase in the amount of free gp52 was not detected by scanning a fluorogram exposed for 5 days (Fig. 5a, b) . These data suggested that a portion of gp93-130 and gp52 remained associated with each other or with the gC-I complexes even though disulphide bonds between gp52 and gp93-130 were cleaved. Moreover, the non-covalent bonds between gp93-130 and gp52 were not disrupted by extraction from the viral envelope with a non-ionic detergent. When the gC-I complexes obtained from DTT-treated virions were reduced, the glycoproteins and their relative amounts were the same as that from the control virions which were not exposed to DTT prior to extraction (Fig. 5 c) . After immunoprecipitating extracts from the DTT-treated virions with a gp52 MAb, a gp93-130 MAb (3C2) was used. When this was done no additional radioactivity was immunoprecipitated (data not shown). These data showed that there was no free gp93-130 left in the extracts.
Discussion
The primary objective of this study was to characterize the relationships between the various glycoproteins and complexes in the family of HCMV glycoprotein complexes designated gC-I (Gretch et al., 1988a) . Another objective was to determine the neutralizing activity of MAbs reactive with epitopes uniquely expressed on antigenically distinct glycoproteins in the gC-I complexes. Previous analysis has indicated that gC-I glycoproteins are derived from a single precursor glycoprotein reported to have an Mr of 158000 to 170000 (Britt & Auger, 1986; Britt & Vugler, 1989; Gretch et al., 1988b; Taylor et al., 1988) . After final processing events the Mr of this glycoprotein is reduced to 138 000 (Gretch et al., 1988 b) . This glycoprotein is a stable intermediate and is apparently cleaved to generate gp52 and gp93 (Gretch et al., 1988b ). An additional gC-I glycoprotein has been described with an M~ of 130000 (gpl30) (Taylor et al., 1988) . Glycoprotein gp130 may reflect alternative processing of gp138, which may involve differences in glycosylation or differences in proteolytic cleavage. The reactivity of our gp93-130 MAbs with vaccinia-gBm165 showed that gp93-130 was derived from the N-terminal portion of the gene encoding gp52. This result is consistent with previous work which suggested that gC-I glycoproteins are derived from a single gene product (Britt & Auger, 1986; Britt & Vugler, 1989; Gretch et al., 1988b; Taylor et al., 1988) . In SDS-PAGE, gp93-130 tends to form a broad band, whereas gp52 tends to form a more focused band. The diffuse band formed by gp93-130 in SDS-PAGE may be due to the fact that gp93-130 is more heavily glycosylated than gp52 (Britt & Vugler, 1989) . In addition, this diffuse band could contain gp93 and gp 130, as described by others (Farrar & Greenaway, 1986) . If this band contains both gp93 and gpl30, then both glycoproteins lack the epitopes recognized by our gp52-specific MAbs. These epitopes were apparently removed by post-translational proteolytic cleavage of gp158 to produce the mature gp93-130. We were able to obtain neutralizing MAbs which recognized either gp52 or gp93-130 and, to our knowledge, there have been no previous reports of MAbs recognizing gp93-130 or of MAbs which recognize gp93-130 neutralizing HCMV. Furthermore, the mechanisim of neutralization of our gp93-130 MAbs was different from that of our gp52 MAbs in that they did not require complement. We have also found that there are human antibody responses to both gp52 and gp93-130 (data not shown) which suggests that human immune responses to both gp52 and gp93-130 may be important in limiting infection with HCMV.
The radioactive labelling experiments presented in this report showed that gp93-130 contained O-linked glycans, but that gp52 did not, which is consistent with previous observations (Britt & Vugler, 1989) . It is interesting to note that both glycoproteins contain a significant amount of hydroxyamino acids, based on analysis of the gene encoding them (Spaete et al., 1988) . Nonetheless, only gp93-130 contains significant amounts of O-linked glycans. Very little is known about the signals involved in O-glyccsylation and thus, the glycoproteins of gC-I may provide a model for their study.
Our preparations of gC-I contained a glycoprotein of high Mr designated gp158. After Coomassie blue staining, gp158 appeared to be a minor component relative to gp52 and gp93-130 and could therefore have been a precursor present due to contamination of the virus preparation with infected cell membranes. This appeared to be the case for two reasons. First, its Mr was similar to that reported for gC-I precursor glycoproteins (Britt & Auger, 1986; B ritt & Vugler, 1989; Gretch et al., 1988b) and, second, this glycoprotein was not detected when virions were purified by a combination of differential centrifugation and sucrose gradient purification (Gretch et al., 1988a, b; Kari et al., 1986) . Glycoprotein gp 158 did contain galactose and/or galactosamine residues, suggesting that it was at a late stage of processing. One explanation for these results is that gp158 was processed to a similar extent as gp52 and gp93-130 with the exception of the proteolytic step which would cleave it into the lower Mr gC-I glycoproteins. These results also suggest that the proteolytic step which generates gp52 and gp93-130 occurs late in the processing of the gB gene product.
The glycoprotein complexes which compose the gC-I family found in the envelope of HCMV have Mrs which are heterogeneous, gC-I complexes with an Mr of 250 000 appear to contain two copies of gp52 and two copies of gp93, which makes them a multimer of the 150000 Mr complexes which contain one copy of each of gp52 and gp93 (Farrar & Greenaway, 1986) . These complexes do not appear to be artefacts of isolation. The inter-complex disulphide bonds forming the 250000 Mr complexes are much more susceptible to DTT than intra-complex disulphide bonds as almost complete reduction of intercomplex disulphide bonds was observed after 30 min, whereas intra-complex disulphide bonds were present after 120 min of exposure to DTT. The presence of disulphide bonds between viral glycoproteins which differ in their sensitivity to reducing agents has been reported for influenza virus (Selimova et al., 1988) . In this case a gradual loss of infectivity was observed as the concentration of reducing agent increased, which suggested that maintenance of higher order structures was important to the functions of the surface glycoproteins. Because HCMV envelope glycoproteins other than gC-I were reduced at the same time as gC-I (data not shown), any loss of infectivity of HCMV could be attributed to disruption of more than one family of complexes. Thus, it would be difficult to determine the effect reduction of gC-I would have on infection. The reason for intercomplex disulphide bonds is not clear but they may be important in stabilizing these complexes and defining the surface architecture of HCMV, which is most likely to be important in maintaining the ability to infect a host cell. Although intra-complex disulphide bonds were more stable in the presence of DTT, there was still some reduction of these bonds. This was demonstrated by the fact that gp52 and gp93-130 could be dissociated by SDS-PAGE without further exposure to reducing agents. Thus, even though gp52 and gp93-130 were no longer disulphide-linked, they remained associated even after being extracted from the virion envelope with a non-ionic detergent. This implies that these glycoproteins have strong non-covalent bonds which were only disrupted by the harsh preparative conditions for SDS-PAGE. Analysis of the gene encoding gC-I glycoproteins has shown that gp52 contains a transmembrane domain which would anchor it in the envelope of HCMV (Spaete et al., 1988) , whereas the portion of this gene encoding gp93-130 contains no transmembrane domain. It is interesting to speculate that gp93-130 may remain associated with the envelope of HCMV by its association with gp52. These associations apparently include both covalent and non-covalent bonds.
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